Oncotarget

Clinical Research Papers:

Long-term supplementation of decaffeinated green tea extract does not modify body weight or abdominal obesity in a randomized trial of men at high risk for prostate cancer

Nagi B. Kumar _, Roshni Patel, Julio Pow-Sang, Philippe E. Spiess, Raoul Salup, Christopher R. Williams, Michael J. Schell

PDF |  HTML  |  Author Information  |  Order a Reprint

 

Metrics: PDF 105 views  |   HTML 130 views  |   ?  


Abstract

Nagi B. Kumar1, Roshni Patel1, Julio Pow-Sang2, Philippe E. Spiess2, Raoul Salup3, Christopher R. Williams4 and Michael J. Schell5

1H. Lee Moffitt Cancer Center and Research Institute, Inc., 12902 Magnolia Drive, MRC/CANCONT, FL 336129497, Tampa

2H. Lee Moffitt Cancer Center and Research Institute, Inc., 12902 Magnolia Drive, WCB-GU PROG, FL 336129497, Tampa

3James A Haley Veterans Hospital, 13000 Bruce B Downs Blvd, FL 33612, Tampa

4Associate Professor of Surgery, Director, Urologic Oncology, Research, and Robotic Surgery, University of Florida and Shands Medical Center, Jacksonville, FL 32209

5H. Lee Moffitt Cancer Center and Research Institute, Inc., 12902 Magnolia Drive, MRC/BIOSTAT, FL 336129497, Tampa

Correspondence to:

Nagi B. Kumar, email: nagi.kumar@moffitt.org

Keywords: green tea catechins, prostate cancer risk, obesity, body mass index and abdominal obesity

Received: November 16, 2016     Accepted: June 03, 2017     Published: June 29, 2017

ABSTRACT

Background: Evidence continues to demonstrate the role of obesity in prostate carcinogenesis and prognosis, underscoring the need to identify and continue to evaluate the effective interventions to reduce obesity in populations at high risk. The aim of the study was to determine the effect of daily consumption of decaffeinated green tea catechins (GTC) formulation (Polyphenon E® (PolyE)) for 1 year on biomarkers of obesity in men who are at high risk for prostate cancer.

Materials and Methods: A randomized, double-blinded trial was conducted targeting 97 men diagnosed with HGPIN or ASAP. Subjects were randomized to receive GTC (PolyE) (n = 49) or placebo (n = 48) for 1 year. Anthropometric data were collected at baseline, 6 and 12 months and data analyzed to observe change in weight, body mass index (indicator of obesity) and waist: hip ratio (indicator of abdominal obesity).

Results: Decaffeinated GTC containing 400 mgs of the bioactive catechin, EGCG administered for 1 year to men diagnosed with ASAP and HGPIN appears to be bioavailable, well tolerated but not effective in reducing biomarkers of obesity including body weight, body mass index and waist: hip ratio.

Conclusions: The results of our trial demonstrates that men who are obese and at high risk for prostate cancer should resort to effective weight management strategies to reduce obesity and not resort to ineffective measures such as taking supplements of green tea to reduce biomarkers of obesity. Changes in body mass index and abdominal obesity seen in other studies were potentially due to caffeine and not GTC.

Author Information

Nagi B. Kumar
Primary Contact  _

Roshni Patel

Julio Pow-Sang

Philippe E. Spiess

Raoul Salup

Christopher R. Williams

Michael J. Schell


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 18858